Prostate cancer Posts on Medivizor
Navigation Menu

Prostate cancer Posts on Medivizor

Does a dose of 20 or 25 mg/m2 of cabazitaxel benefit patients with castration-resistant prostate cancer?

Does a dose of 20 or 25 mg/m2 of cabazitaxel benefit patients with castration-resistant prostate cancer?

Posted by on Sep 8, 2020 in Prostate cancer | 0 comments

In a nutshell This study aimed to assess the effectiveness and safety of two doses of cabazitaxel  (Jevtana) (20 or 25 mg/m2) in the treatment of castration-resistant prostate cancer (CRPC) in the real-world practice. The study found that a lower dose of cabazitaxel benefited patients at high risk of having side...

Read More

Looking for patients with high risk prostate cancer to trial a radiation treatment

Looking for patients with high risk prostate cancer to trial a radiation treatment

Posted by on Aug 30, 2020 in Prostate cancer | 0 comments

In a nutshell This trial is aiming to investigate the effectiveness of stereotactic body radiotherapy (SBRT) boost for the treatment in patients with high-risk prostate cancer (PCa). The main outcome that will be measured will be the quality of life (QoL) of patients. This study is being carried out in Ontario, Canada.  The details PCa is the...

Read More

Searching for patients with metastatic castration resistant prostate cancer to trial a biological treatment combination

Searching for patients with metastatic castration resistant prostate cancer to trial a biological treatment combination

Posted by on Aug 15, 2020 in Prostate cancer | 0 comments

In a nutshell This trial is examining the effectiveness of cabozantinib (Cabometyx) combined with atezolizumab (Tecentriq) for metastatic castration-resistant prostate cancer (mCRPC; cancer that is no longer responding to hormone therapy). The main outcomes to be measured are progression-free survival (PFS) and overall survival (OS) of...

Read More

Can high-risk prostate cancer be treated with high-dose-rate brachytherapy, external beam radiotherapy plus long-term androgen deprivation therapy?

Can high-risk prostate cancer be treated with high-dose-rate brachytherapy, external beam radiotherapy plus long-term androgen deprivation therapy?

Posted by on Aug 9, 2020 in Prostate cancer | 0 comments

In a nutshell This study looked at whether the use of high-dose (HD) brachytherapy (BT) and hypofractionated external beam radiotherapy (EBRT) plus androgen-deprivation therapy (ADT) as a means of treatment for very high-risk prostate cancer (PCa). The study found that this treatment had significant benefits for patients with high-risk...

Read More

Is there an association between statin use and the risk of prostate cancer mortality?

Is there an association between statin use and the risk of prostate cancer mortality?

Posted by on Jul 31, 2020 in Prostate cancer | 0 comments

In a nutshell This study evaluated whether there was an association between statin (a type of cholesterol-lowering medication) use and prostate cancer (PCa) mortality. This study found that stain use resulted in lower rates of PCa-specific mortality, in particular with the use of hydrophilic statins. Some background PCa is one of the most common...

Read More

COVID-19 with Cancer

COVID-19 with Cancer

Posted by on Jul 31, 2020 in Blog, Breast cancer, Colorectal cancer, Coronavirus / COVID-19, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 3 comments

Recent research presented at a virtual meeting of the American Association for Cancer Research 1 indicates the need for greater care and continued social distancing for those who are in treatment for cancer and – in one study that was presented – those who have a recent history of cancer (the research looked at people from 2015 to the...

Read More

Comparing the effectiveness of apalutamide, darolutamide and enzalutamide in treating nonmetastatic castration-resistant prostate cancer

Comparing the effectiveness of apalutamide, darolutamide and enzalutamide in treating nonmetastatic castration-resistant prostate cancer

Posted by on Jul 26, 2020 in Prostate cancer | 0 comments

In a nutshell The study compared outcomes of apalutamide (A; Erleada), darolutamide (D; Nubeqa), and enzalutamide (E; Xtandi) in treating nonmetastatic castration-resistant prostate cancer (nmCRPC). The authors found that A and E had better metastasis-free survival (MFS) compared to D. Some background Men with CRPC fail to respond to...

Read More

Can androgen deprivation therapy combined with docetaxel plus prednisone improved outcomes in patients with metastatic hormone-sensitive prostate cancer?

Can androgen deprivation therapy combined with docetaxel plus prednisone improved outcomes in patients with metastatic hormone-sensitive prostate cancer?

Posted by on Jul 26, 2020 in Prostate cancer | 0 comments

In a nutshell The aim of this study was to evaluate the safety and effectiveness of combining androgen deprivation therapy (ADT) with docetaxel (Taxotere) plus prednisone (Deltasone) in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The study found that this combination improved the outcomes of these...

Read More

The effects of bipolar androgen therapy in men with metastatic castration resistant prostate cancer

The effects of bipolar androgen therapy in men with metastatic castration resistant prostate cancer

Posted by on Jul 19, 2020 in Prostate cancer | 0 comments

In a nutshell The study evaluated outcomes of bipolar androgen therapy (BAT) in men with metastatic castration-resistant prostate cancer (mCRPC) who were continuing drugs targeting androgen receptors (AR). The authors found that BAT was clinically effective in such patients. Some background BAT refers to sequential injections with testosterone in men...

Read More

Comparing the long-term effects of two intensity modulated radiation therapies in localized prostate cancer

Comparing the long-term effects of two intensity modulated radiation therapies in localized prostate cancer

Posted by on Jun 28, 2020 in Prostate cancer | 0 comments

In a nutshell The study compared the long-term effects of moderate hypofractionated intensity-modulated radiation therapy (H-IMRT) and conventionally fractionated IMRT (C-IMRT) on outcomes in patients with localized prostate cancer (PC). The authors found that H-IMRT was similarly effective compared to C-IMRT after 10 years of therapy in such...

Read More